Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Notes Payables (2021 - 2023)

Longeveron (LGVN) posted quarterly Notes Payables of $457000.0 for Q1 2023, down 73.9% quarter-over-quarter from $1.8 million in Q4 2022.

Longeveron (LGVN) Notes Payables (2021 - 2023) Analysis & Trends

Longeveron's Notes Payables history runs 3 years deep, the most recent figure standing at $457000.0 for Q1 2023.

  • In Q1 2023, Notes Payables changed N/A year-over-year to $457000.0; the TTM figure through Mar 2023 stood at $457000.0 (changed N/A YoY), while the FY2022 annual figure was $1.8 million, up 171.47% from the prior year.
  • Notes Payables for Q1 2023 stood at $457000.0, down from $1.8 million in the prior quarter.
  • The five-year high for Notes Payables was $1.8 million in Q4 2022, with the low at $457000.0 in Q1 2023.
  • The 3-year median for Notes Payables is $645000.0 (2021), against an average of $951000.0.
  • Peak annual rise in Notes Payables reached 171.47% in 2022, while the deepest fall reached 171.47% in 2022.
  • Longeveron's Notes Payables stood at $645000.0 in 2021, then soared by 171.47% to $1.8 million in 2022, then sank by 73.9% to $457000.0 in 2023.
  • Business Quant data shows LGVN's Notes Payables at $457000.0 in Q1 2023, $1.8 million in Q4 2022, and $645000.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00

Historic Data

Download Data
DateValue
Mar 31, 2023 457,000.00
Dec 31, 2022 1.75 Mn
Dec 31, 2021 645,000.00